[Pneumococcal vaccines. New conjugate vaccines for adults]. / Vacunas antineumocócicas. Nuevas vacunas conjugadas para el adulto.
Enferm Infecc Microbiol Clin
; 33(9): 617-24, 2015 Nov.
Article
en Es
| MEDLINE
| ID: mdl-26474708
ABSTRACT
Pneumococcal infections are a significant cause of morbidity and mortality, and are one of the 10 leading causes of death worldwide. Children under 2 years have a higher incidence rate, followed by adults over 64 years. The main risk group are individuals with immunodeficiency, and those with anatomical or functional asplenia, but can also affect immunocompetent persons with certain chronic diseases. Significant progress has been made in the last 10 years in the prevention of these infections. Until a few years ago, only the 23-valent non-conjugate pneumococcal vaccine was available. Its results were controversial in terms of efficacy and effectiveness, and with serious limitations on the type of immune response induced. The current possibility of using the 13-valent conjugate vaccine in adults has led to greater expectations in improving the prevention of pneumococcal disease in these age groups.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones Neumocócicas
/
Vacunas Neumococicas
Tipo de estudio:
Incidence_studies
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Humans
/
Middle aged
País/Región como asunto:
Europa
Idioma:
Es
Revista:
Enferm Infecc Microbiol Clin
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
/
MICROBIOLOGIA
Año:
2015
Tipo del documento:
Article